The purpose of this study was to test the anti-cancer properties and pro-apoptotic effects of the polyherbal formulation MAT20 as a complementary treatment. Moringa oleifera (Moringa), Phyllanthus emblica (Amla) and Ocimum sanctum (Tulsi), these 3 herbs were used to formulate MAT20, which contain phytochemicals that are known to display anti-cancer properties. In this study, we hypothesized that MCF-7 breast cancer cells treated with MAT20 would show increased cytotoxicity compared to its individual plant extracts.

In South Asian countries, the major cause of oral cancer is reported to be chewing paan, which is comprised of betel leaf daubed with slaked lime paste and areca nut. To investigate how paan may contribute to the onset of cancer, the authors treated two immortalized cell lines with extracts of betel leaf, areca nut, and lime and evaluated how these treatments affected cell proliferation and cell death. Initial results indicate that while betel leaf alone may inhibit cell growth, areca nut promoted cancer cell survival and proliferation, even when co-treated with betel leaf. These data suggest that areca nut could exacerbate the progression of oral cancer in humans.

Stem cells are at the forefront of research in regenerative medicine and cell therapy. Two essential properties of stem cells are self-renewal and potency, having the ability to specialize into different types of cells. Here, Park and Jeong took advantage of previously identified stem cell transcription factors associated with potency to differentiate umbilical cord mesenchymal stem cells (US-MSCs) from morphologically similar fibroblasts. Western blot analysis of the transcription factors Klf4, Nanog, and Sox2 revealed their expression was unique to US-MSCs providing insight for future methods of differentiating between these cell lines.

Since cancer cells inhibit T-cell activity, the authors investigated a method to reverse T-cell disfunction with gene therapy, so that the T-cells would become effective once again in fighting cancer cells. They used the inhibition of proprotein convertases (PCSK1) in T cells and programmed death-ligand 1 (CD274) in cancer cells. They observed the recovery of IL-2 expression in Jurkat cells, with increased recovery noted in a co-culture sample. This study suggests a novel strategy to reactivate T cells.

The authors compare RNA expression profiles across three human cell types following infection with MERS-CoV

Cellular senescence plays a key role in aging cells and is attributed to a number of disease and pathology. These authors find that genetic editing of both RPS6KB1 and PPARGC1A revitalizes a human skin fibroblast cell line.

In this study, the authors identify new potential targets to treat advanced diffuse large B-cell lymphoma after treatment relapse and loss of CD19 expression.

Cholesterol is a major component of neuronal cell membrane and myelin sheath. In this study, the authors either transfected Neuro 2A cells with CYP46A1 cDNA or treated the cells with 24SHC. Cells expressing CYP46A1 had significantly less viability compared to the negative control. Up to 55% reduction in cell viability was also observed in 24S-HC-treated cells. This work supports that CYP46A1 and 24S-HC could directly trigger cell death. The direct involvement of 24S-HC in cell death provides further evidence that 24S-HC can be a promising biomarker for diagnosing brain damage severity.

A microbial fuel cell is a system to produce electric current using biochemical products from bacteria. In this project authors operated a microbial fuel cell in which glucose was oxidized by Shewanella oneidensis in the anodic compartment. We compared the power output from biomineralized manganese or cobalt oxides, reduced by Leptothrix cholodnii in the cathodic compartment.

In this study, Imani et al. investigate whether a new proprietary herbal formulation, HF1, can inhibit expression of immune suppressor protein PD-L1. PD-L1 is a transmembrane protein that can be expressed by cancer cells to assist in their ability to avoid attacks from the immune system. Work from this study demonstrates that HF1 treatment can reduce expression of PD-L1 in cultured cancer cells, implicating HF1 as a potential new cancer therapy.